Exploring high dividend stocks with yields of 13-14% but potential risks, including the possibility of dividend cuts in the ...

This is the final accrual related to the litigation expense and there will be no additional litigation accruals moving forward. With increasing profitability, a strong balance sheet and upcoming ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Greetings and welcome to the Fulgent Genetics Q3 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode ...

Research and development expenses ... and accrued interest was $55.9 million. In Q3 and in early Q4, we raised gross proceeds ...

Among the approximately 90% of trial ... and accrued interest receivable as of September 30, 2024. The Company believes it has sufficient capital resources to fund its operations into the third ...

Our research and development expenses were $40.5 million for the quarter ... ADC pipeline of vobra duo and the TAMARACK clinical trial. Our selling, general, and administrative expenses were ...

Understanding cash flow is key to measure both current cash inflows and outflows, and to forecast future cash positions.The balance of cash flows could ... accounts payables, accrued expenses, income ...